Inve India ▾

Wanbury share price & results

Wanbury Limited· Healthcare

Results to
Jun 2026
Ownership as of
Sept 2026

API manufacturer of Metformin, Sertraline and Tramadol for regulated export markets (US, EU, Brazil), alongside a legacy branded acute-therapy formulations business in India

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue166 ₹ crore+1.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin9.8 %−5.2 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit3.2 ₹ crore−76.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity96.55 %−41.0 ptsFY Mar 2025 vs FY Mar 2024Trailing twelve monthsTTM to Jun 2025Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow marginUnavailable−2.0 ptsFY Mar 2025 vs FY Mar 2024Fiscal yearFY · period unavailableNot in the analysed materials. No older figure is substituted.
Revenue growth (YoY)12.32 %−7.1 ptsFY Mar 2025 vs FY Mar 2024Trailing twelve monthsTTM to Jun 2025Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹176.02 +5.77% · +₹9.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −25.2% 1Y

₹150₹200₹250₹300₹350Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹235.3 on 24 Oct 2025 → ₹176.02. High ₹344.75 (15 Jul 2026), low ₹163.34 (27 Jan 2026).

Previous close
₹166.42
Market cap
₹606 Cr
52-week range
₹163.34 – ₹344.75
One year
−30.82%
Price to earnings (TTM to Jun 2025)
14.43×
Return on equity (TTM to Jun 2025)
96.55%

Overview

Symbol
NSE:WANBURY
Exchange
NSE
Currency
INR

What Wanbury Limited does

Based on the company's own presentations, annual report and earnings calls.

Wanbury manufactures Active Pharmaceutical Ingredients (APIs) at two plants in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra), producing molecules such as Metformin (antidiabetic), Sertraline (antidepressant), Tramadol (pain management), Paroxetine, Mefenamic acid and Diphenhydramine, sold mostly to regulated export markets. It also runs a legacy branded Formulations business in India, marketing acute-therapy products across anti-cold & cough, pain/anti-inflammatory, antacid and supplement categories under an outsourced (contract) manufacturing model, distributed through its own field force, C&F agents and distributor network.

Segments

  • API (Active Pharmaceutical Ingredients)
  • Formulations
Manufacturing plants
2 API plants (Tanuku, Andhra Pradesh & Patalganga, Maharashtra)
Cumulative installed reactor capacity
500 KL (400 KL at Tanuku + 96 KL at Patalganga)
API molecule portfolio
6 molecules (Metformin, Sertraline, Tramadol, Paroxetine, Mefenamic acid, Diphenhydramine) + 1 new anaesthetic
USFDA-approved API facilities
2
Global regulatory approvals
US-FDA, EDQM (Europe), ANVISA (Brazil), KFDA (South Korea), COFEPRIS (Mexico), WHO-GMP
DMF/CEP filings with regulatory authorities
70 total (64 approved, 6 pending)
Founded 1988Headquarters Vashi, Navi Mumbai, Maharashtra, IndiaEmployees 1,200 (9MFY26) Company website

Your own record

Start an Inve Case for Wanbury Limited

Free account: one company. Everything above stays public.

Write why you follow Wanbury Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Wanbury Limited

Guides on how to read this kind of business and the numbers that matter.